Nonetheless, our study confirms the tolerability and safety of anti-CD20 drugs in real-world clinical practice for patients with neuroinflammatory diseases of the CNS, particularly multiple sclerosis. This evidence concerns the gene MS4A1 and multiple sclerosis.